MC

544.1

-1.98%↓

SANES

5.555

-9.84%↓

BNP

68.74

-8.1%↓

CS.FR

37.94

-4.53%↓

ALV

339.2

-4.32%↓

MC

544.1

-1.98%↓

SANES

5.555

-9.84%↓

BNP

68.74

-8.1%↓

CS.FR

37.94

-4.53%↓

ALV

339.2

-4.32%↓

MC

544.1

-1.98%↓

SANES

5.555

-9.84%↓

BNP

68.74

-8.1%↓

CS.FR

37.94

-4.53%↓

ALV

339.2

-4.32%↓

MC

544.1

-1.98%↓

SANES

5.555

-9.84%↓

BNP

68.74

-8.1%↓

CS.FR

37.94

-4.53%↓

ALV

339.2

-4.32%↓

MC

544.1

-1.98%↓

SANES

5.555

-9.84%↓

BNP

68.74

-8.1%↓

CS.FR

37.94

-4.53%↓

ALV

339.2

-4.32%↓

Search

Evotec AG

Geschlossen

BrancheFinanzen

5.9 -0.51

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

5.75

Max

6.08

Schlüsselkennzahlen

By Trading Economics

Einkommen

55M

-40M

Verkäufe

2.8M

185M

Gewinnspanne

-21.437

Angestellte

5,007

EBITDA

58M

-45M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+116.95% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

17. Apr. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.1B

Vorheriger Eröffnungskurs

6.41

Vorheriger Schlusskurs

5.9

Nachrichtenstimmung

By Acuity

29%

71%

92 / 542 Ranking in Finance

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

Evotec AG Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Juni 2024, 13:17 UTC

Market Talk

Evotec's Profit Outlook Looks Gloomy -- Market Talk

Peer-Vergleich

Kursveränderung

Evotec AG Prognose

Kursziel

By TipRanks

116.95% Vorteil

12-Monats-Prognose

Durchschnitt 12.8 EUR  116.95%

Hoch 14 EUR

Tief 11.6 EUR

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Evotec AG – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

2

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

5.76 / 6.075Unterstützung & Widerstand

Kurzfristig

Weak Bearish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

92 / 542 Ranking in Finanzen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Evotec AG

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.